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Involvement of Low-Density Lipoprotein Receptor in the Pathogenesis
of Pulmonary Hypertension
Soban Umar, MD, PhD; Gregoire Ruffenach, PhD; Shayan Moazeni, MSc; Mylene Vaillancourt, MSc; Jason Hong, MD;
Christine Cunningham, BSc; Nancy Cao, BS; Sara Navab, MD; Shervin Sarji, MSc; Min Li, PhD; Lisa Lee, MD; Greg Fishbein, MD;
Abbas Ardehali, MD; Mohamad Navab, PhD; Srinivasa T. Reddy, PhD; Mansoureh Eghbali, PhD
Background-—Recently, we and others have reported a causal role for oxidized lipids in the pathogenesis of pulmonary
hypertension (PH). However, the role of low-density lipoprotein receptor (LDL-R) in PH is not known.
Methods and Results-—We examined the role of LDL-R in the development of PH and determined the efﬁcacy of high-density
lipoprotein mimetic peptide 4F in mitigating PH. Explanted human lungs and plasma from patients with PH and control subjects
were analyzed for gene expression, histological characteristics, and lipoprotein oxidation. Male LDL-R null (LDL-R knockout) mice
(12–15 months old) were fed chow, Western diet (WD), WD with 4F, and WD with scramble peptide for 12 weeks. Serial
echocardiography, cardiac catheterization, oxidized LDL assay, real-time quantitative reverse transcription–polymerase chain
reaction, and histological analysis were performed. The effect of LDL-R knockdown and oxidized LDL on human pulmonary artery
smooth muscle cell proliferation was assessed in vitro. LDL-R and CD36 expression levels were signiﬁcantly downregulated in the
lungs of patients with PH. Patients with PH also had increased lung lipid deposits, oxidized LDL, E06 immunoreactivity, and plasma
oxidized LDL/LDL ratio. LDL-R knockout mice on WD developed PH, right ventricular hypertrophy, right ventricular dysfunction,
pulmonary vascular remodeling, ﬁbrosis, and lipid deposition in lungs, aortic atherosclerosis, and left ventricular dysfunction, which
were prevented by 4F. Interestingly, PH in WD group preceded left ventricular dysfunction. Oxidized LDL or LDL-R knockdown
signiﬁcantly increased proliferation of human pulmonary artery smooth muscle cells in vitro.
Conclusions-—Human PH is associated with decreased LDL-R in lungs and increased oxidized LDL in lungs and plasma. WD-fed
LDL-R knockout mice develop PH and right ventricular dysfunction, implicating a role for LDL-R and oxidized lipids in PH. ( J Am
Heart Assoc. 2020;9:e012063. DOI: 10.1161/JAHA.119.012063.)
Key Words: low-density lipoprotein receptor • oxidized lipids • oxidized low-density lipoprotein • pulmonary hypertension •
Western diet
P ulmonary hypertension (PH) is a pulmonary vasculardisease characterized by a pathologically increased mean
pulmonary arterial pressure (≥25 mm Hg).1 The cause of PH is
multifactorial and includes pulmonary endothelial cell
dysfunction, smoothmuscle cell proliferation, extracellularmatrix
remodeling, and inﬂammation.2 Pulmonary vasoconstriction and
remodeling contribute to increased pulmonary vascular resis-
tance, leading to right ventricular (RV) hypertrophy and failure.
Recently, we and others have reported a critical role for
oxidized lipids in the pathogenesis of PH.2–6 RV lipid
accumulation and lipotoxicity have also been reported in
humans and animal models of PH.7–9
Low-density lipoproteins (LDLs) and high-density lipopro-
teins (HDLs) are the major source of lipid transport and are
platforms for lipid oxidation in the circulation. Both LDL and
HDL were reported to be dysfunctional in patients with PH.4
Zhang et al recently investigated the role of lectin-like
oxidized LDL receptor (LDL-R)-1 (OLR1) in PH and showed
that OLR1 promotes pulmonary artery (PA) smooth muscle
cell dedifferentiation under hypoxic conditions.10 However,
the role of LDL-R, which binds and internalizes LDL into the
cell, has never been investigated in PH.
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HDL levels are signiﬁcantly depressed in patients with PH,
which is associated with worse clinical outcomes.11 HDL’s
major protein, apolipoprotein A-1, is attributable for the
beneﬁcial effects of HDL on atherosclerosis. The apolipopro-
tein A-1 mimetic peptide 4F restores vascular endothelial
function and has been shown to have anti-inﬂammatory
properties in lungs. 4F also decreases airway hyperrespon-
siveness and oxidative stress.12–14 4F has recently been
shown to rescue PH in rodents.3 However, the precise
mechanism of how 4F rescues development of PH is unclear.
Our recent study demonstrated that this effect is mediated
through the induction of downstream effector of 4F,
microRNA-193-3p.3
In this report, we show that the expression levels of LDL-R
and fatty acid transporter CD36 are signiﬁcantly reduced in
lungs of patients with PH. Moreover, oxidized LDL in both
lungs and plasma is signiﬁcantly elevated in patients with PH.
LDL-R knockout (LDL-R KO) mouse model has been studied
extensively for the development of hyperlipidemia, atheroscle-
rosis, and left ventricular (LV) dysfunction,15 but it has not
been investigated for the development of PH and RV
dysfunction. We now show, for the ﬁrst time, that Western
diet (WD)–fed LDL-R KO mice develop PH. Furthermore, we
also demonstrate a potential therapeutic role of 4F peptide on
WD-induced PH in LDL-R KO mice. Mechanistically, we show
knockdown of LDL-R resulted in signiﬁcantly increased
proliferation of human PA smooth muscle cells (hPASMCs)
in vitro, and oxidized LDL treatment is sufﬁcient to induce
hPASMC proliferation in vitro.
Methods
Full details of all experimental protocols are presented in Data
S1. The data that support the ﬁndings of this study are
available from the corresponding author on reasonable
request.
Human Subjects
After institutional review board approval, human explanted
lung tissue from patients with PH (PH group; n=7) were
obtained. Discarded donor lung tissue or lung tissue from
patients without evidence of PH undergoing lung transplants
at UCLA Medical Center were used as controls for the study
(control group; n=8). Clinical characteristics of human
subjects are given in Table S1. For human samples, either
the human subjects gave informed consent or this require-
ment was waived.
Human Lung Microarray Data Analysis for LDL-R
and CD36
Gene expression data for LDL-R and CD36 from 13 control
human lungs and 18 lungs with pulmonary arterial hyperten-
sion were retrieved from Gene Expression Omnibus using the
GSE15197 data set.16 A heat map was generated using
normalized expression values in the pheatmap package in R.
Oxidized LDL Assay
Human plasma was collected from patients with PH (PH; n=9)
and subjects without PH (control; n=12). Plasma oxidized LDL
was quantiﬁed using the ELISA assay for oxidized LDL,
according to the manufacturer’s instructions.
Real-Time Polymerase Chain Reaction
Total RNA was puriﬁed from human lungs using the Trizol
method. Quantitative real-time reverse transcription–poly-
merase chain reaction was performed. The LDL-R and CD36
gene expression was assessed using gene-speciﬁc primers.
GAPDH was used as a reference control for normalization.
Animals and Treatments
All animal studies were performed in accordance with the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals. Middle-aged male LDL-R KO mice (12–
Clinical Perspective
What Is New?
• This research demonstrates an important role of low-density
lipoprotein (LDL) receptor and oxidized LDL in the patho-
genesis of pulmonary hypertension (PH).
• PH is associated with decreased LDL receptor and CD36 in
human lungs, along with increased inﬂammation and
oxidized lipids. Western diet–fed LDL receptor knockout
mice develop PH that precedes left ventricular dysfunction.
• Targeting oxidized lipids with high-density lipoprotein
mimetic peptides is a potential novel therapeutic strategy
for treating PH.
What Are the Clinical Implications?
• There is a growing body of evidence implicating oxidized
lipids in the pathogenesis of PH; however, the role of LDL
receptor has never been investigated in PH.
• This research may take us one step further in understanding
how oxidized lipids promote PH.
• High-density lipoprotein mimetic peptides may serve as
novel therapeutic agents for PH and right ventricular
dysfunction.
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15 months old) were fed either chow (n=16) or WD (n=27) for
12 weeks. Mice on WD were randomly divided into 3 groups:
WD (n=9), WD together with apolipoprotein A1 mimetic (HDL
mimetic) peptide D-4F (WF+4F group; n=11), or WD together
with scramble peptide (WD+SCRM group; n=7) in drinking
water for 12 weeks. A group of chow-fed mice received 4F
(chow+4F group; n=8). Serial echocardiography was per-
formed to monitor cardiopulmonary hemodynamics and the
development of PH and RV dysfunction. Direct RV and LV
catheterization was performed terminally, and RV hypertrophy
index was calculated as weight ratio of RV/(LV+interventric-
ular septum). Aorta, RV, LV, and lung tissue were collected.
Short-term effects of WD were also studied in LDL-R KO mice
(n=14) over 2 weeks. LV and RV function were noninvasively
assessed by echocardiography at baseline, week 1, and week
2, followed by invasive RV systolic pressure (RVSP) recording
before euthanasia. For comparative analysis of lung oxidized
lipids (E06 immunostaining), lung sections from male Sprague
Dawley rats from control, monocrotaline-induced PH (60 mg/
kg; single SC injection and followed up for 30 days), and
Sugen-hypoxia (20 mg/kg; single SC injection, followed by
3 weeks of 10% O2 and 2 weeks of normoxia) groups were
also used.
Echocardiography and Cardiopulmonary
Hemodynamic Measurements
Transthoracic echocardiography was performed to monitor
cardiopulmonary hemodynamics using a Vevo 2100 high-
resolution image system. Ejection fraction (EF; %) was
measured using M-mode images. A 30-MHz linear transducer
was used for pulmonary pulsed-wave Doppler echocardiogra-
phy of PA ﬂow. PA acceleration time (PAAT) was determined
by calculating time taken from the start of ﬂow to maximal
velocity using echocardiogram software.
The RVSP and LV systolic pressure were measured directly
by inserting a catheter into the RV or LV just before
euthanasia. Heart and lung tissues were removed rapidly
under deep anesthesia for preservation of protein and RNA
integrity.
Gross Histologic Analysis, Tissue Preparation,
and Imaging
The RV wall, the LV wall, and the interventricular septum were
dissected. The ratio of the RV to LV plus septal weight [RV/
(LV+interventricular septum)] was calculated as the Fulton
index of RV hypertrophy. Lungs were frozen, and transversal
4- to 6-lm sections were obtained with a cryostat. Parafﬁn-
embedded control lung sections, obtained from the UCLA
(University of California Los Angeles) pathology laboratory,
were sectioned at 5 lm. Images were acquired using a
confocal microscope (Nikon). Lung tissue sections were
stained with Masson’s trichrome, Oil Red O, immunoﬂuores-
cence (CD68, oxidized LDL, and OLR-1), and immunohisto-
chemistry (EO6).
Immunoﬂuorescence and Immunohistochemical
Stainings
Brieﬂy, lung sections were ﬁxed and incubated with normal goat
serum to block the background and incubated with primary
antibodies at 4°C overnight. Sections were then incubated with
the secondary antibody and mounted for imaging using
Fluoromount-G with 40,6-diamidino-2-phenylindole.
For immunohistochemistry, endogenous peroxidase activ-
ity was inhibited by incubating the lung sections with H2O2.
The sections were then incubated with normal goat serum to
block the nonspeciﬁc binding. The sections were incubated
with the appropriate primary antibodies at 4°C overnight and
incubated with horseradish peroxidase–conjugated secondary
antibody for 1 hour at room temperature. Sections were
stained with 3,30-diaminobenzidine as a substrate and
mounted using Permount. The images were acquired using a
confocal microscope.
Masson’s Trichrome and Oil Red O Staining
Masson’s trichrome and Oil Red O stainings were performed
according to the manufacturer’s protocol, and images were
acquired with a confocal microscope.
Quantiﬁcation of Pulmonary Vascular
Remodeling, Lung Fibrosis, and Lipid Deposition
For assessment of pulmonary arteriolar wall thickness, only
distal pulmonary arteries <100 lm were quantiﬁed using
ImageJ software. Percentage of fully muscularized, partially
muscularized, and nonmuscularized arteries was also calcu-
lated. Pulmonary ﬁbrosis was quantiﬁed using a grid over the
images of lungs. Results are expressed as the percentage
occupied by ﬁbrosis to the total area examined. Percentage
lipid deposition was quantiﬁed in lung sections using ImageJ
software.
Assessment of hPASMC Proliferation With LDL-R
Knockdown
hPASMCs at passage 6 to 7 were seeded in a 96-well plate at
a density of 8000 cells/well. After overnight incubation at
37°C, cells were transfected with 100 nmol/L LDL-R siRNA or
scramble siRNA, following the protocol of Lipofectamine
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RNAiMAX Transfection Reagent. After 4 hours of transfection,
cells were starved with 0.1% SMGS (Smooth muscle growth
supplement) Media 231 for 40 hours. Cell viability was
measured by Cell Counting Kit-8 (DoJindo Molecular Tech-
nologies). LDL-R mRNA levels were measured by reverse
transcription–polymerase chain reaction from parallel exper-
iments using cells seeded in a 6-well plate.
Assessment of hPASMC Proliferation With
Oxidized LDL Incubation
hPASMCs at passage 5 to 6 were seeded in a 96-well plate at
a density of 8000 cells/well. After 24 hours of incubation at
37°C, cells were starved with 0.1% SMGS Media 231
overnight, followed by oxidized LDL (20, 50, and 100 lg/
mL) treatment for 24 hours. Cell viability was measured by
Cell Counting Kit-8.
Reagents
Primary antibodies used were anti-CD68, anti–oxidized LDL,
anti-OLR1, and anti-E06. Secondary antibodies used were
goat anti-rat IgG antibody Alexa Fluor 594 and goat anti-rabbit
Alexa Fluor 594 antibody.
Statistical Analysis
Unpaired t-tests and 1-way ANOVA tests were used to compare
between groups using GraphPad Prism for Windows. When
signiﬁcant differences were detected, individual mean values
were compared by post hoc tests (Tukey or Dunnett) that
allowed for multiple comparisons. P<0.05 was considered
statistically signiﬁcant. Values are expressed as meanSEM.
Results
Human PH Is Associated With Decreased Lung
LDL-R and CD36 Expression and Increased
Plasma Oxidized LDL/LDL Ratio
As expected, patients with PH had signiﬁcantly elevated RVSP
compared with controls (857 in PH versus 343 mm Hg in
controls; P<0.001; Figure 1A, Table S1). Next, we assessed
LDL-R and CD36 expression in lungs of control and PH
groups. Real-time qPCR showed that LDL-R and CD36
transcript expression levels were signiﬁcantly decreased in
lungs of patients with PH (both P<0.05; Figure 1B and 1C).
Similarly, analysis of the gene expression data for LDL-R
and CD36 from 13 control human lungs and 18 PH lungs,
retrieved from Gene Expression Omnibus using the online
available GSE15197 data set (Figure 1D), demonstrated
signiﬁcantly decreased LDL-R (49%; false discovery rate,
0.0022) and CD36 expression (51%; false discovery rate,
0.0023) in PH compared with control lungs.
Next, we measured the plasma levels of circulating LDL
and oxidized LDL in controls and patients with PH and
calculated the ratio of oxidized LDL/LDL to assess for the
oxidized LDL fraction. We found a signiﬁcant increase in
plasma oxidized LDL/LDL ratio in the patients with PH
compared with controls (P<0.05; Figure 1E, Table S2).
LDL-R KO Mice Fed a WD Develop PH and RV
Dysfunction
In our human studies, we observed a signiﬁcant downregulation
of LDL-R expression in lungs of patients with PH, along with an
increase in oxidized LDL/LDL ratio. Next, we hypothesized that
WD may induce PH in LDL-R KO mice. We used middle-aged
LDL-R KO mice (12-15 months old) to better mimic the clinical
scenario. Middle-aged LDL-R KO mice fed a WD for 12 weeks
developed PH, as demonstrated by a decrease in PAAT
(16.11.12 ms versus 21.81.12 ms; P<0.0001) and an
increase in RVSP (40.92.04 versus 29.20.79 mm Hg;
P=0.0003) in the WD and compared with chow (Figure 2A
through 2C). PH in LDL-R KO mice on WD was also associated
with an increase in RV hypertrophy index (0.410.01 versus
0.230.02; P<0.0001) and decrease in RV EF (43.631.37%
versus 67.70.66%; P<0.0001) compared with LDL-R KO mice
on chow diet (Figure 2D and 2E).
Our data show, for the ﬁrst time, that LDL-R KO mice on
WD develop PH, RV hypertrophy, and RV dysfunction.
WD-Induced PH in LDL-R KOMice Is Prevented by 4F
We found4F treatment prevented developmentof PH inLDL-RKO
mice fed with WD, whereas scrambled peptide treatment
(WD+SCRM group) had no signiﬁcant effect on the severity of
PH (PAAT: 19.41.12 ms in WD+4F and 14.91.12 ms in
WD+SCRM [P=0.0006]; RVSP: 28.51.12 in WD+4F and
38.50.92 mm Hg in WD+SCRM [P<0.0001]; Figure 2C).
Furthermore, 4F therapy resulted in prevention of RV dysfunc-
tion (RV EF: WD+SCRM=45.141.63%, WD+4F=65.51.05%
[P<0.0001]) (Figure 2D and 2E). PH in WD-fed LDL-R KO mice
was also associated with increase in body weight in WD and
WD+SCRM groups that was prevented by 4F treatment
(Figure S1B).
PH Precedes the Development of LV Dysfunction
in WD-Fed LDL-R KO Mice
We also examined the effect of WD on LV function of middle-
aged LDL-R KO mice. We found that WD induced LV
dysfunction in LDL-R KO mice because LV EF was signiﬁcantly
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lower compared with mice on chow diet (46.22.09% versus
64.61.47%; P=0.0001; Figure 3A through 3C). LV dysfunction
was prevented by 4F therapy (LV EF: WD+SCRM=46.11.86%,
WD+4F=63.81.72% [P<0.0001]; Figure 3A and 3B). LV
pressures were signiﬁcantly increased in WD and WD+SCRM
groups (LV systolic pressure, mm Hg: chow=72.92.95,
WD=99.35.44, WD+SCRM=98.93.02, WD+4F=82.74.35
[P=0.007 for chow versus WD; P=0.014 for WD+SCRM versus
WD+4F) (Figure 3C).
To investigate whether PH in our model is secondary to LV
dysfunction, we performed a time course experiment for
noninvasive assessment of development of PH through
measurement of PAAT and LV function through LV EF over
12 weeks via serial transthoracic echocardiography (Fig-
ure 4A and 4B). Interestingly, we observed that the develop-
ment of PH preceded the development of LV dysfunction in
this model. In fact, we observed a signiﬁcant decrease in
PAAT as early as 1 week after initiation of WD, whereas we
observed a more gradual decline in LV EF over 12 weeks
(Figure 4A and 4B). To further conﬁrm the presence of RV
pressure overload as early as 1 and 2 weeks after initiation of
WD, we performed invasive right heart catheterization at
weeks 1 and 2 after initiation of WD in LDL-R KO mice. Our
results conﬁrmed that RVSP was signiﬁcantly increased at 1
and 2 weeks after WD compared with baseline (both P<0.001
versus baseline; P<0.001 for 1 versus 2 weeks), whereas LV
EF was unchanged (Figure 4C through 4E). Hence, we believe
that PH precedes LV dysfunction in this model. This obser-
vation supports a direct effect of oxidized lipids in inducing PH
in this model, which is in agreement with our previously
published work.3
Pulmonary Vascular Remodeling, Fibrosis, and
Lipid Deposition in LDL-R KO Mice Fed WD Are
Prevented by 4F
Pulmonary vascular remodeling is a hallmark of PH. PH in WD-
fed LDL-R KO mice was associated with pulmonary vascular
remodeling, as demonstrated by increased pulmonary
arteriolar medial hypertrophy in WD group that was prevented
by 4F therapy (% wall thickness: chow=23.31.20,
WD=31.91.21, WD+SCRM=29.62.82, WD+4F=24.10.79;
A B
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Figure 1. Human pulmonary hypertension (PH) is associated with decreased lung low-density lipoprotein
receptor (LDL-R) and CD36 expression and increased plasma oxidized LDL/LDL ratio. A, Right ventricular
systolic pressure (RVSP; mm Hg; control, n=6; PH, n=6). B, Normalized LDL-R mRNA expression in human
lungs (control, n=8; PH, n=6). C, Normalized CD36 mRNA expression in human lungs (control, n=7; PH,
n=7). D, Heat map showing normalized expression of LDL-R and CD36 in 13 controls and 18 human lungs
with PH from the GSE15197 microarray data set. E, Plasma oxidized LDL/LDL ratio in controls and patients
with PH (controls, n=12; PH, n=9). *P<0.05, ***P<0.001. CTRL indicates control; ox, oxidized.
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Figure 5A and 5D). The increase in % wall thickness in WD and
WD+SCRM groups was associated with an increase in the
percentage of partially and fully muscular arteries (Figure 5E).
PH in LDL-R KO mice on WD was also associated with the
development of both interstitial and perivascular pulmonary
ﬁbrosis that was prevented by 4F therapy (% ﬁbrosis:
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Figure 2. Low-density lipoprotein receptor knockout (LDL-R KO) mice fed a Western diet (WD) develop pulmonary hypertension, right
ventricular (RV) hypertrophy, and RV dysfunction that is prevented by 4F. A, Pulmonary artery (PA) pulsed-wave Doppler and M-mode
echocardiographic images of the RV. B, PA acceleration time (PAAT; ms). C, Right ventricular systolic pressure (RVSP; mm Hg). D, Right
ventricular hypertrophy Fulton index [RV weight/(left ventricular weight+interventricular septum weight)]. E, Right ventricular ejection
fraction (RV EF; %) in LDL-R KO mice fed with chow (n=5–8), Western diet (WD; n=6–12), WD+scrambled peptide (SCRM) (n=5–7), and
WD+4F peptide (n=6–8). *P<0.05, **P<0.01, ***P<0.001.
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chow=23.31.20, WD=31.91.21, WD+SCRM=29.62.82,
WD+4F=24.10.79; Figure 5B and 5F). We also observed
increased lung lipid deposition in WD and WD+SCRM groups
that was prevented by 4F treatment (Figure 5C, G). The lung
weight was also signiﬁcantly increased in the WD-fed LDL-R
KO mice, most likely as a result of vascular remodeling,
ﬁbrosis, and lipid deposition (Figure S1C).
LDL-R KO Mice on WD Demonstrate Increased
Lung Inﬂammation and Oxidized Lipids
Oxidized lipids are known to induce inﬂammation. We assessed
lung inﬂammation in our mouse model using CD68 as a marker
for macrophages. We observed increased CD68 positive
alveolar macrophage inﬁltration in WD-fed LDL-R KO mice
(chow=11810 versus WD=27863 cells/mm2; Figure 6A
through 6C). Treatment with 4F prevented the increase in
CD68-positive cells in the lungs, whereas scramble peptide had
no effect (WD+4F=14316; WD+SCRM=24844 cells/mm2
Figure 6A through 6C).
We assessed oxidized phospholipids in the lungs of LDL-R
KO mice on chow versus WD and in 2 well-established
experimental models of PH in rats (monocrotaline-induced PH
and Sugen-hypoxia–induced PH) compared with controls
using EO6 antibody. We found a signiﬁcant increase in EO6
immunolabeling in the vasculature, perivascular regions, and
the macrophages in the PH lungs (Figure 6D and 6E). We also
assessed OLR1 in lungs of LDL-R KO mice and observed an
increase in OLR1 staining in pulmonary vascular cells and
macrophages in lungs of LDL-R KO mice on WD for 2 and 12
weeks (Figure 6F).
WD Induces Lipid Deposition in Aorta and Heart
of LDL-R KO Mice
LDL-R KO mice are known to develop atherosclerosis when
challenged with a WD. As expected, we observed increased
lipid deposition in the aorta in WD and WD+SCRM groups,
which was prevented by 4F therapy (Figure S2). Similarly, we
also observed increased lipid deposition in RV and LV in WD
and WD+SCRM groups that was prevented by 4F treatment
(Figure S2). RV lipid deposition and lipotoxicity have been
reported in patients and mice with PH.7,8 We also stained the
heart sections of the mice with trichrome staining but did not
observe an increase in either RV or LV ﬁbrosis (Figure S2).
Human PH Is Associated With Increased Lipid
Deposition, Inﬂammation, EO6, and Oxidized LDL
Immunolabeling in Lungs
As we observed increased lipid deposition and inﬂammation in
the lungs of LDL-R KO mice on WD diet, we also assessed
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B, LV ejection fraction (EF; %). C, LV systolic pressure (LVSP; mm Hg) in LDL-R KO mice fed with chow
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human lungs from control and PH groups for lipid deposition
and inﬂammation. We observed lipid deposition in both the lung
parenchyma as well as the pulmonary vasculature (Figure 7A).
We also assessed oxidized phospholipids in the lungs using EO6
antibody and found a signiﬁcant increase in immunolabeling in
the macrophages and perivascular regions in the PH lungs
(Figure 7B). CD68 immunoﬂuorescence staining demonstrated
increased CD68-positive macrophages in the lungs of patients
with PH (Figure 7C). As we had observed an increase plasma
oxidized LDL/LDL ratio in patients with PH, we assessed the
lungs for oxidized LDL immunolabeling and found an overall
increase in oxidized LDL in perivascular regions and macro-
phages in PH lungs (Figure 7D).
Knockdown of LDL-R or Oxidized LDL Treatment
Results in hPASMC Proliferation in Vitro
To assess the mechanistic role of LDL-R in PA smooth muscle
cell proliferation, we performed in vitro cell experiments using
hPASMCs. Similar to the human lung tissue ﬁndings and the
LDL-R KO mouse model, we performed LDL-R knockdown in
hPASMCs using siRNA technique, which was conﬁrmed by
PCR (Figure 8A). Interestingly, LDL-R knockdown resulted in
signiﬁcantly increased proliferation of hPASMCs in vitro,
which is a hallmark of the pulmonary vascular disease of PH
(Figure 8B).
Next, we investigated the potential of oxidized LDL to
induce hPASMC proliferation in vitro. We found that oxidized
LDL alone is sufﬁcient to induce hPASMC proliferation in vitro
in a dose-dependent manner (Figure 8C).
Discussion
Herein, we demonstrate, for the ﬁrst time, that patients with PH
have decreased LDL-R and CD36 expression in their lungs,
along with increased plasma oxidized LDL/LDL ratio. There is
also evidence of increased inﬂammation and lipid deposition in
the lungs of patients with PH. Furthermore, LDL-R KO mice fed
WD for 12 weeks developed PH that preceded the development
of LV dysfunction, both of which were prevented by
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apolipoprotein A-1 mimetic (HDL mimetic) peptide 4F therapy.
Incubation of hPASMCs with oxidized LDL and LDL-R knock-
down resulted in signiﬁcantly increased proliferation in vitro.
PH is a multifactorial disease with poor prognosis. The
pathogenesis of PH encompasses a complex interplay of
molecular and cellular events, leading to pulmonary vascular
remodeling, inﬂammation, and oxidative stress.2 Over the past
decade, we and others have demonstrated the critical
implication of lipids, particularly oxidized lipids, in the
pathogenesis of PH.2–5,17,18 There is a growing body of
evidence demonstrating that increased levels of oxidized
lipids are found in the plasma and lungs of patients and
rodents with PH.3–5,17,18
PH is linked to metabolic syndrome and its associated
conditions.19 The high-fat, high-cholesterol containing WD has
long been implicated in the development of metabolic
syndrome, which encompasses a cluster of conditions,
including obesity, insulin resistance, hyperlipidemia, and
systemic hypertension. All these conditions are risk factors
for atherosclerosis.20 Furthermore, WD-fed LDL-R KO mice
develop obesity and insulin resistance,21,22 conditions asso-
ciated with both metabolic syndrome and PH.23,24 The
absence of LDL-Rs, which regulate the LDL levels in the
bloodstream, results in the development of atherosclerosis in
LDL-R KO mice.22 When a critical concentration is reached,
LDL phospholipids are oxidized. LDL cholesterol is a well-
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known marker of cardiovascular risk, and its levels are
decreased in patients with pulmonary arterial hypertension
and associated with an increased risk of death.25 We also
found a trend toward lower circulating LDL cholesterol levels
in patients with PH (Table S1), but an increased circulating
oxidized LDL/LDL ratio (Figure 1E).
We found a signiﬁcant decrease in LDL-R and fatty acid
transporter CD36 expression in the lungs of patients with PH
(Figure 1B through 1D). In addition, we found an increase in
oxidized LDL in the plasma and lungs of patients with
(Figures 1E and 7D). Oxidized phospholipid marker EO6
immunoreactivity was also increased in lungs with PH,
speciﬁcally in the macrophages (Figure 7B). We found a
similar increase in lung EO6 immunolabeling in mice with WD-
induced PH and in 2 established experimental models of PH in
rats induced with monocrotaline and Sugen-hypoxia. We also
observed an increase in lung OLR1 immunolabeling in
pulmonary vascular cells and macrophages in WD-fed LDL-R
KO mice, which is consistent with the recent report on OLR1
immunolabeling in human lungs with pulmonary arterial
hypertension.26 The decrease in LDL metabolizing machinery
in the lungs may have led to decreased reverse cholesterol
transport, resulting in elevated oxidized LDL levels. These
oxidized phospholipids are known to mediate the develop-
ment of fatty streaks in atherosclerosis.27 Furthermore,
oxidized LDL has been shown to increase vascular smooth
muscle cell proliferation and migration in the context of
atherosclerosis.28 It is plausible that oxidized LDL may have
similar effects on pulmonary vascular smooth muscle cells
promoting PH phenotype. In fact, in our cell culture experi-
ments, we observed that incubation of hPASMCs with
oxidized LDL resulted in increased proliferation, a hallmark
of pulmonary vascular disease in PH. In a separate set of
experiments, we demonstrated that LDL-R knockdown in
hPASMCs resulted in signiﬁcantly increased proliferation
in vitro, implicating LDL-R in pulmonary vascular remodeling.
The colocalization of EO6 and oxidized LDL with CD68+
macrophages suggests possibility of a link between inﬂam-
mation and oxidized lipids (Figure 7). Oxidized LDL induces
signiﬁcant inﬂammatory response in vascular cells, resulting
in the production of monocyte chemoattractant protein-1.
Oxidized LDL also binds monocyte chemoattractant protein-1
and retains its ability to recruit monocytes.29 In addition,
OLR1, known to be an endothelial receptor of oxidized LDL,
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Figure 7. Human pulmonary hypertension (PH) is associated with increased lipid deposition, inﬂamma-
tion, EO6, and oxidized low-density lipoprotein (LDL) immunolabeling in lungs. A, Oil Red O staining (red)
showing lipid deposition in lungs and pulmonary arteries (PAs) of control subjects and patients with PH.
B, Immunoperoxidase staining for E06 in lungs of control subjects and patients with PH. C,
Immunoﬂuorescence staining for CD68+ macrophages (red) in lung sections from control subjects and
patients with PH. Nuclei are stained with 40,6-diamidino-2-phenylindole (DAPI) in blue. D, Immunoﬂuores-
cence staining showing coimmunolabeling of CD68 (green) and oxidized LDL (red) in lung sections from
control subjects and patients with PH.
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has recently been linked to the development of PH via
increased oxidative stress and phenotypic switching of PA
smooth muscle cells.10,30
Previously, LDL-R KO mice on WD for prolonged period
(18 weeks) have been shown to develop atherosclerosis and LV
dysfunction,15 but it has never been tested whether they
develop PH and RV dysfunction. In the current study, we used
middle-aged LDL-R KO mice that are susceptible to oxidative
stress. Interestingly, in addition to the development of LV
dysfunction, we found these mice also developed PH that was
associated with pulmonary vascular remodeling and pulmonary
ﬁbrosis. The contribution of LV dysfunction and atherosclerosis
to the development of PH and RV dysfunction cannot be ruled
out. The presence of pulmonary vascular remodeling and
pulmonary ﬁbrosis point toward a possible direct effect of WD-
induced oxidative stress on the lung. To examine whether PH is
secondary to LV dysfunction, we serially monitored the mice
with echocardiography and demonstrated that WD-induced
decrease in PAAT preceded the decrease in LV EF, highlighting
the susceptibility of the pulmonary circulation to the effects of
WD. This decrease in PAAT was sustained over the 12-week
period. LV EF, on the other hand, had a more gradual decline
over the 12-week period, only reaching signiﬁcance at
10 weeks. The abrupt decrease in PAAT in 1 week was
conﬁrmed by invasive right heart catheterization, in the
absence of any change in LV EF, further conﬁrming that PH
precedes the development of LV dysfunction (Figure 4).
Plasma HDL levels are signiﬁcantly depressed in patients
with PH and are associated with increased mortality and
clinical deterioration.11 Apolipoprotein A-I (the major compo-
nent of HDL) and its mimetic peptides (4F) prevent the
formation or inactivate inﬂammatory LDL-derived oxidized
phospholipids.31 Navab et al demonstrated that 4F inhibited
atherosclerosis by reducing inﬂammation.32 Furthermore, 4F
restores vasodilation, reduces inﬂammation, and prevents
heart hypertrophy in LDL-R KO mice on WD.12,15,33 In a
previous study, we demonstrated that 4F effectively rescued
rats and wild-type mice with established PH. We discovered
that microRNA-193-3p was signiﬁcantly downregulated in
lungs of rodents with PH and that 4F restores its expression
levels.3 Interestingly, in the current study, we found that the
use of 4F peptide prevented the development of PH and RV
dysfunction in WD-fed LDL-R KO mice (Figure 2).
Hansmann et al conducted experiments with apolipoprotein
E–deﬁcient mice, another mouse strain susceptible to the
effects of oxidized lipids, and demonstrated that they developed
PH when they were fed high-fat diet.34 However, this had not
been tested in LDL-R KO mice, which share similar associated
conditions, such as metabolic syndrome, obesity, and insulin
resistance. In the same study, Hansmann et al also demon-
strated that PH could be reversed by peroxisome proliferator-
activated receptor-c activation.34 The peroxisome proliferator-
activated receptor-c inhibits the expression of proinﬂammatory
genes and regulates fat cell development, inhibiting the devel-
opment of atherosclerosis in LDL-R KO mice.35
There is accumulating evidence that RV dysfunction in PH
may be secondary to maladaptive fatty acid metabolism and
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lipid accumulation, resulting in RV lipotoxicity.7,8 Talati et al
also found lipid deposition in the BMPR2 (Bone Morphoge-
netic Protein Receptor) mutant RVs, which was exacerbated in
the presence of WD.7 We also observe RV lipid deposition
along with RV hypertrophy and dysfunction in our model of PH
(Figure 2, Figure S2).
One of the limitations of our study is the use of 4F peptide
as a preventive rather than a rescue therapy. We have
previously shown that 4F peptide can rescue PH in rodent
models.3 On the basis of our previous results, we anticipate
that 4F is a potent rescue agent for oxidized lipid–induced PH.
Conclusions
In conclusion, human PH is associated with downregulation of
LDL-R and CD36 in the lungs, along with increased oxidized
lipids and inﬂammatory markers (Figure 9). WD-fed LDL-R KO
mice develop PH and biventricular dysfunction. Development
of PH preceded LV dysfunction, suggesting a susceptibility of
the pulmonary circulation to the effects of the WD. HDL
mimetic peptide 4F prevented the development of PH and RV
dysfunction. Future studies are warranted to understand the
precise role of LDL-Rs and oxidized lipids in PH pathogenesis.
Perspectives
Despite considerable advances, the survival of patients with
PH remains poor. Signiﬁcant evidence exists implicating
oxidized lipids, metabolic syndrome, and insulin resistance in
PH. However, the role of LDL-R and oxidized LDL has not been
investigated in PH. The present study demonstrates that PH is
associated with decreased LDL-R and CD36 in human lungs,
along with increased inﬂammation and oxidized lipids. WD-fed
LDL-R KO mice develop PH that precedes LV dysfunction.
Targeting oxidized lipids with HDL mimetic peptides is a
potential novel therapeutic strategy for treating PH.
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Data S1. 
 
Supplemental Methods 
 
Human subjects 
After institutional review board approval, human explanted lung tissue from patients with 
PH (PH group, n=7) were obtained (Table S1). Discarded donor lung tissue or lung tissue 
from patients without evidence of PH undergoing lung transplants at UCLA Medical 
Center were used as controls for the study (CTRL group, n=8).  
 
Human lung microarray data analysis for LDL-R and CD36 
Gene expression data for LDL-R and CD36 from 13 Control human lungs and 18 PAH 
lungs was retrieved from GEO using the GSE15197 dataset1. A heatmap was generated 
using normalized expression values in the pheatmap package in R. 
 
Oxidized LDL Assay 
Human plasma was collected from PH patients (PH, n=9) and subjects without PH 
(CTRL, n=12) using EDTA as anticoagulant, and centrifuged for 15 minutes at 1,000×g 
at 2-8oC within 30 minutes of collection. Samples were stored in aliquots at -80oC until 
use. Plasma samples were diluted 1:500 in sterile 1X PBS for the assay. Plasma oxidized 
LDL (ox-LDL) were quantified using the ELISA assay for ox-LDL (Cloud-Clone Corp. 
cat#CEA527Hu) according to the manufacturer’s instructions. 
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Real time PCR 
Total RNA was purified from human lungs using the Trizol method. Two micrograms of 
total RNA were reverse transcribed to cDNA using the Omniscript RT kit (Qiagen), 
according to the manufacturer's instructions (Qiagen). Quantitative real-time reverse 
transcriptase-polymerase chain reaction (QRT-PCR) was performed using iTaq universal 
SYBR green supermix (Bio-Rad cat#1725121). The LDL-R and CD36 gene expression 
was assessed using gene-specific primers. GAPDH was used as a reference control for 
normalization. Levels of gene expression in each sample were determined with the 
comparative Ct method using Bio-Rad CFX manager 2.1 software.  
The primer sequences were as follows:  
1) LDL-R, F: 5′-CAACTGCGGGGACTGTTCA-3′, R: 5′ 
GGACAGGCATACTCATCGGAC-3′;  
2) CD36, F: 5’-TGCAGTGTAGGACTTTCCTG-3’, R: TCCGGTCACAGCCCATTTT-
3’  
3) GAPDH, F: 5′-CACCATCTTCCAGGAGCGAG-3′; R: 5′-
GACTCCACGACGTACTCAGC-3′.  
For gene expression, thermocycler protocol was as follows: polymerase activation: 30 s 
at 95°C, then denaturation 5s at 95°C, and annealing/elongation 90s at 60°C for 40 
cycles. 
 
Animals and treatments  
Middle aged male LDL-R KO mice (12-15 months old) were fed either chow (n=16) or 
Western diet (WD, n=27) for 12 weeks. Mice on WD were randomly divided into three 
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groups, WD (n=9), WD together with Apolipoprotein A1 mimetic (HDL mimetic) 
peptide D-4F (WF+4F group, n=11), or WD together with scramble peptide (WD+SCRM 
group, n=7) in drinking water for 12 weeks. A group of chow fed mice received 4F 
(chow+4F group, n=8, Fig. S1). Serial echocardiography was performed to monitor 
cardiopulmonary hemodynamics and the development of PH and RV dysfunction. Direct 
RV and LV catheterization was performed terminally and RV hypertrophy index was 
calculated as weight ratio of RV/(LV+IVS). Aorta, RV, LV and lung tissue were 
collected.  
 
Echocardiography and cardiopulmonary hemodynamic measurements 
Transthoracic echocardiography was performed to monitor cardiopulmonary 
hemodynamics using a Vevo 2100 high-resolution image system (VisualSonics, Toronto, 
Canada). Echocardiograms including B-mode, M-mode and pulsed wave Doppler images 
were obtained under isoflurane aesthesia. Ejection fraction (EF, %) was measured using 
M-mode echocardiographic images. A 30-MHz linear transducer was used to perform the 
pulmonary pulsed-wave Doppler echocardiography of PA flow. The probe was placed in 
a parasternal long-axis position to visualize the PA outflow tract. Pulsed flow Doppler 
imaging was then overlaid to observe the dynamics of blood flow through the PA valve. 
PA acceleration time (PAAT) was determined by calculating time taken from the start of 
flow to maximal velocity using echocardiogram software (Vevo 2100 version: 1.5.0).  
The right ventricular systolic pressure (RVSP) and left ventricular systolic pressure 
(LVSP) were measured directly by inserting a catheter (1.4 F Millar SPR-671, 
ADInstruments) connected to a pressure transducer (Power Lab, ADInstruments) into the 
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RV or LV just before sacrifice. Briefly, for cardiac catheterization, the mice were 
anesthetized with isoflurane. The animals were placed on a controlled warming pad to 
keep the body temperature constant at 37 °C. After a tracheotomy was performed, a 
cannula was inserted, and the animals were mechanically ventilated. After a midsternal 
thoracotomy, mice were placed under a stereomicroscope (Zeiss, Hamburg, Germany) 
and a pressure-conductance catheter (model 1.4 F Millar SPR-671) was introduced via 
the apex into the RV or LV and positioned towards the pulmonary or aortic valve 
respectively. The catheter was connected to a signal processor (ADInstruments) and 
pressures were recorded digitally. After recording the pressures, heart and lung tissues 
were removed rapidly under deep anesthesia for preservation of protein and RNA 
integrity. 
 
Gross histologic analysis, tissue preparation and imaging 
The right ventricular (RV) wall, the left ventricular (LV) wall, and the interventricular 
septum (IVS) were dissected. RV, LV, IVS and lungs were weighed. The ratio of the RV 
to LV plus septal weight [RV/(LV + IVS)] was calculated as the Fulton index of RV 
hypertrophy. Lungs were fixed in 4% paraformaldehyde (PFA) in 0.1 M Na2HPO4 and 23 
mM NaHPO4 (pH 7.4) for 4 h on ice. The tissue was then immersed in ice-cold 20% 
sucrose in 0.1 M Na2HPO4 and 23 mM NaHPO4 (pH 7.4) overnight to cryoprotect the 
tissue, mounted using OCT, and transversal 4–6μm sections were obtained with a 
cryostat. Paraffin embedded control lung sections, obtained from the UCLA pathology 
lab, were sectioned at 5µm. Images were acquired using a confocal microscope (Nikon). 
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Lung tissue sections were stained with Masson’s trichrome, Oil-Red-O, 
immunofluorescence (CD68, oxLDL) and immunohistochemistry (EO6).  
Immunofluorescence and immunohistochemistry staining 
Lung sections (5μm) were fixed in 4% paraformaldehyde. The sections were then washed 
with PBS+0.1% Tween20 three times and incubated with 5% normal goat serum in PBS 
for one hour to block the background. Following blocking, the sections were incubated 
with primary antibodies in PBS+2% normal goat serum at 4°C overnight. Sections were 
then washed with PBS three times, incubated with the secondary antibody in PBS+2% 
normal goat serum at room temperature for one hour. After washing the secondary 
antibody with PBS three times, the sections were mounted for imaging using 
Fluoromount-G with DAPI (Molecular Probes) (ThermoFisher cat#00-4959-52).  
For immunohistochemistry, endogenous peroxidase activity was inhibited by incubating 
the lung sections with 0.3% H2O2 in PBS for 20 min at room temperature followed by 
washing with PBS thrice. The lung sections were then incubated with 10% normal goat 
serum in PBS containing 0.1% Triton for 30 min at room temperature to block the 
nonspecific binding. The sections were incubated with the appropriate primary antibodies 
in PBS+0.1% Triton+ 1% normal goat serum at 4oC overnight, and washed 3 times with 
PBS+0.1% Triton. The sections were incubated with HRP-conjugated secondary 
antibody (1:200 dilution) in PBS+0.1% Triton+ 1% normal goat serum, for 1 h at room 
temperature, washed with PBS+0.1% Triton three times, and stained with 3,3’-
diaminobenzidine (DAB) as a substrate (10X DAB solution + stable buffer) for 5-10 min. 
The DAB was rinsed with dH2O and stained with hematoxylin for 1 min, washed under 
running tap water for 10 min. Dehydration was then performed by incubating in 50%, 
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70%, 96%, 100% ethanol and xylene. Sections were mounted using Permount (Fisher 
Scientific). The images were acquired using a laser scanning confocal microscope (Nikon 
Eclipse E 400).  
 
Masson’s Trichrome and Oil-Red-O staining 
Masson Trichrome staining was performed according to the manufacturer's protocol 
(Sigma), and images were acquired with a confocal microscope (Nikon).  
For Oil-Red-O staining, frozen sections cut at 4-6m, were fixed in formalin, and briefly 
washed with running tap water for 1-10 mins. Sections were rinsed with 60% isopropanol 
and stained with freshly prepared Oil-Red-O working solution for 15 mins. Sections were 
rinsed with 60% isopropanol. Nuclei were lightly stained with 5 dips of haematoxylin. 
Sections were rinsed with distilled water and mounted in aqueous mounting medium. 
Images were acquired with a confocal microscope (Nikon). 
 
Quantification of pulmonary vascular remodeling, lung fibrosis and lipid deposition 
For assessment of pulmonary arteriolar wall thickness, only distal pulmonary arteries less 
than 100μm were quantified (3–4 vessels per mouse; number of mice: chow=7, WD=10, 
WD+Scramble=4, WD+4F=7) using ImageJ software. Stitched images of entire lung 
sections were obtained using 10x objective using a confocal microscope. Pulmonary 
arteriolar wall thickness was calculated by subtracting diameter of the lumen from total 
diameter of the vessel, divided by total diameter of the vessel. As the diameter of the 
vessel and lumen are not usually similar in different directions, pulmonary arteriolar wall 
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thickness was measured in two different directions and averaged. Assessment of percent 
fully muscular, partially muscular and non-muscular arteries was also made (Fig. 5). 
Pulmonary fibrosis was quantified using a grid over stitched images of lungs that divided 
the field of view into 100 squares, each collagenous tissue (blue stain) filled square in the 
grid was scored as 1 (present) or 0 (absent). Results are expressed as the percentage 
occupied by fibrosis to the total area examined (number of mice: chow=7, WD=11, 
WD+Scramble=7, WD+4F=6). Percent lipid deposition was quantified in lung sections 
using ImageJ software (number of mice: chow=4, WD=4, WD+Scramble=4, WD+4F=4). 
 
Reagents 
Primary antibodies used were anti-CD68 (Rat anti Mouse CD68, Bio-Rad cat# 
MCA1957), anti-ox-LDL (Rabbit polyclonal oxLDL orb10973 from Biorbyt), anti-E06 
(Mouse Monoclonal Antibody, IgM Anti-Oxidized Phospholipid, Avanti Polar Lipids, 
Inc.) and anti-LOX1 (anti-OLR1; Rabbit polyclonal, Abcam cat#ab60178). Secondary 
antibodies used were goat anti-rat IgG secondary antibody Alexa Fluor 594, and goat 
anti-rabbit Alexa Fluor 594 secondary antibody. 
 
Statistics  
Unpaired T-tests and one-way ANOVA tests were used to compare between groups using 
GraphPad Prism for Windows. When significant differences were detected, individual 
mean values were compared by post-hoc tests (Tukey or Dunnett) that allowed for 
multiple comparisons. P < 0.05 was considered statistically significant. Values are 
expressed as mean ± SEM.  
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Table S1. Comparison between clinical characteristics of controls (CTRL) and 
patients with PH. 
         
   
    CTRL, n=17 PH, n=9 P   
  Sex: female, n 2 5 0.004   
  Age, y 54±4 50±2 0.572   
 
Diagnosis, (n) - 
iPAH (4), ILD-PH 
(3), CTD-PH (2) 
 
- 
 
 
NYHA Class, (n) - 
Class 3 (2), Class 
4 (1) 
-  
 
Therapies, (n) - 
PDE5 inhibitor 
(6), ET1R 
inhibitor (5), 
Prostacyclin (5) 
- 
 
 Combination therapy, n - 6 -  
  6MWD, min 213±34 (n=6) 177±34 (n=6) 0.487   
  RVSP, mmHg 34±3 (n=6) 85±7 (n=6) <0.001   
  mPAP, mmHg 24±1 (n=6) 55±6 (n=6) <0.001   
  PVR, dyn•s•cm
-5 178±26 (n=4) 653±208 (n=4) 0.064   
  CO, L•min
-1 6.0±0.5 (n=6) 5.6±1.0 (n=5) 0.749   
  CI, L•min•cm
-2 2.8±0.3 (n=6) 3.1±0.8 (n=4) 0.640   
  LDL cholesterol, mg•dL
-1 98±12 (n=12) 77±7 (n=6) 0.285   
  HDL cholesterol, mg•dL
-1 48±5 (n=12) 41±2 (n=6) 0.367   
  Triglycerides, mg•dL
-1 118±18 (n=12) 97±15 (n=6) 0.445   
  Total cholesterol,mg•dL
-1 170±14 (n=12) 137±4 (n=6) 0.131   
  Body Mass Index 27±1.3(n=16) 23±1.1 (n=6) 0.102   
 
Values are mean±SEM. 6MWD indicates 6-minutes walking distance; iPAH, idiopathic 
pulmonary arterial hypertension; ILD-PH, interstitial lung disease associated PH; CTD-
PH, connective tissue disease associated PH; CI, cardiac index; CO, cardiac output; HDL, 
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high-density lipoprotein; LDL, low-density lipoprotein; WHO FC, World Health 
Organization functional class; mPAP, mean pulmonary arterial pressure; mRAP, mean 
right atrial pressure; PVR, pulmonary vascular resistance; RVSP, right ventricular 
systolic pressure.    
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Table S2. Statistics. 
  Figure Comparison P-value   
  1A CTRL vs. PH <0.001   
  1B CTRL vs. PH <0.05   
 1C CTRL vs. PH <0.05  
 1E CTRL vs. PH <0.05  
 
2B 
Chow vs. WD                    
Chow vs. 
WD+SCRM 
WD vs. WD+4F 
WD+SCRM vs. 
WD+4F 
<0.001 
             <0.001 
 
              <0.05 
              <0.01 
  
 
2C 
Chow vs. WD          
Chow vs.                 
WD+SCRM 
WD vs. WD+4F 
WD+SCRM vs. 
WD+4F 
           <0.001 
              <0.01 
 
              <0.001 
              <0.001 
  
  
2D 
Chow vs. WD            
Chow vs. 
WD+SCRM 
WD vs. WD+4F 
         <0.001 
              <0.01 
 
              <0.05   
  
2E 
Chow vs. WD 
Chow vs. 
WD+SCRM 
WD vs. WD+4F 
WD+SCRM vs. 
WD+4F 
              <0.001 
              <0.001 
           
              <0.001 
              <0.001    
  
3B 
Chow vs. WD 
Chow vs. 
WD+SCRM 
WD vs. WD+4F 
WD+SCRM vs. 
WD+4F 
<0.001 
             <0.001 
 
             <0.001 
             <0.001    
  
3C 
Chow vs. WD 
Chow vs. 
WD+SCRM 
             <0.05 
             <0.01    
  
4A 
0 Wk vs. 1 Wk 
0 Wk vs. 3 Wk 
0 Wk vs. 5 Wk 
0 Wk vs. 6 Wk 
  0 Wk vs. 10 Wk 
  0 Wk vs. 12 Wk 
             <0.001 
             <0.001 
             <0.001 
             <0.001 
             <0.001 
             <0.001   
  
4B 
  0 Wk vs. 10 Wk 
  0 Wk vs. 12 Wk 
             <0.05 
             <0.01   
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  4C Wk 1 vs. Wk 2             <0.001   
  
5D 
Chow vs. WD 
WD+SCRM vs. 
WD+4F 
            <0.01 
            <0.01    
  
5F 
  
Chow vs. WD 
WD+SCRM vs. 
WD+4F  
 
            <0.01 
            <0.01 
 
    
 
5G 
Chow vs. WD 
Chow vs. 
WD+SCRM 
WD vs. WD+4F 
WD+SCRM vs. 
WD+4F 
            <0.001 
            <0.001 
 
            <0.001 
            <0.001 
  
 
6C 
Chow vs. WD 
Chow vs. 
WD+SCRM 
WD vs. WD+4F 
 
              
             <0.01 
             <0.01 
              
             <0.01 
 
  
 8A Scramble vs. LDL              <0.01  
 8B Scramble vs. LDL              <0.01  
 
8C 
Control vs. 20 
ug/ml 
Control vs. 50 
ug/ml 
Control vs. 100 
ug/ml 
 
 
              <0.05 
 
              <0.05 
 
              <0.01 
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Figure S1. A. Experimental protocol. LDL-R KO mice were fed either regular chow diet, 
Western diet (WD) alone or WD in the presence of scrambled peptide, or HDL mimetic 
4F peptide for 12 weeks. One group of LDL-R KO mice was fed with chow diet in the 
presence of 4F peptide. B. Body weight (g) and C. Lung weight (g) in LDL-receptor 
knockout mice fed with chow (n=8), Western diet (WD, n=12), WD+Scrambled peptide 
(n=7) and WD+4F peptide (n=8). **p<0.01; ***p<0.001. 
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Figure S2. Oil Red O staining showing lipid deposition (red) in aorta (A), right ventricle 
(RV, B), and left ventricle (LV, C), and Masson’s trichrome staining showing heart 
fibrosis (blue) in RV (D) and LV (E) in Chow, WD, WD+Scramble and WD+4F groups.  
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